Clinical Trials Logo

Uterine Neoplasms clinical trials

View clinical trials related to Uterine Neoplasms.

Filter by:

NCT ID: NCT00075400 Completed - Clinical trials for Uterine Carcinosarcoma

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II clinical trial studies the side effects and how well imatinib mesylate works in treating patients with uterine cancer that has failed to respond to initial chemotherapy or has re-grown after therapy. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00072176 Completed - Clinical trials for Endometrial Adenocarcinoma

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back after a period of time during which the cancer could not be detected. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00050440 Completed - Clinical trials for Endometrial Neoplasms

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.

NCT ID: NCT00025506 Completed - Clinical trials for Uterine Carcinosarcoma

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Start date: September 2001
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.

NCT ID: NCT00025467 Completed - Clinical trials for Endometrial Adenocarcinoma

Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor

NCT ID: NCT00006089 Completed - Clinical trials for Endometrial Adenocarcinoma

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Start date: September 18, 2000
Phase: Phase 2
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage III, stage IV, or recurrent endometrial cancer.

NCT ID: NCT00006011 Completed - Clinical trials for Endometrial Adenocarcinoma

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Start date: July 2000
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen plus radiation therapy is more effective for endometrial cancer.

NCT ID: NCT00005840 Completed - Clinical trials for Endometrial Serous Adenocarcinoma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Start date: July 2000
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of combination chemotherapy when given with radiation therapy in treating patients with stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.

NCT ID: NCT00005830 Completed - Clinical trials for Endometrial Adenocarcinoma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Start date: July 2000
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating women who have stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

NCT ID: NCT00002706 Completed - Clinical trials for Endometrial Adenocarcinoma

Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus

Start date: April 1996
Phase: Phase 3
Study type: Interventional

This randomized phase III trial is studying laparoscopic surgery to see how well it works compared to standard surgery in treating patients with endometrial cancer or cancer of the uterus. Laparoscopic surgery is a less invasive type of surgery for cancer of the uterus and may have fewer side effects and improve recovery. It is not known whether laparoscopic surgery is more effective than standard surgery in treating endometrial cancer.